Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE: ABT) expects to close its acquisition of Exact Sciences on March 23, 2026 after receiving all required regulatory clearances. The deal adds cancer screening and precision oncology capabilities, including Cologuard and Oncotype DX, and is expected to contribute ~$3 billion of incremental sales in 2026.
The transaction is projected to accelerate Abbott's 2026 sales growth by ~0.5 percentage points and dilute 2026 adjusted EPS by ~$0.20.
Abbott (NYSE: ABT) reported results from the FreeDM2 randomized controlled trial showing that people with Type 2 diabetes on basal insulin using FreeStyle Libre continuous glucose monitoring (CGM) achieved better glucose control versus fingersticks at four months.
Key findings: HbA1c fell 0.6% (p<0.001) and participants spent ~2.5 more hours/day in the 70–180 mg/dL healthy range (a 10.4% increase). An Italian interventional study of 88 people showed similar benefits at three months.
Abbott (NYSE: ABT) and Real Madrid launched year two of the Abbott Dream Team, a nationwide youth program for 18–19-year-old soccer players offering free selection events, health and nutrition education, and on-field development led by Real Madrid coaches. 16 finalists will receive an all‑expenses‑paid training trip to Madrid and return to lead local health sessions.
Selection events run May–June in Miami, Washington D.C., Houston, Kansas City, Los Angeles and Chicago; participants register at AbbottDreamTeam.com. Marcelo will join as a mentor.
Summary not available.
Exact Sciences (NASDAQ: EXAS) stockholders voted to approve the proposed acquisition by Abbott (NYSE: ABT) at a special meeting held February 20, 2026. Preliminary results showed >99% of votes cast, representing ~67% of outstanding shares as of the January 9, 2026 record date, voted in favor.
Subject to satisfaction or waiver of remaining closing conditions, the transaction is expected to close before the end of the second calendar quarter of 2026. According to the company, each Exact Sciences share will receive $105.00 in cash upon completion, without interest and subject to applicable withholding taxes. Final voting results will be reported on Form 8-K filed with the SEC.
Abbott (NYSE: ABT) declared a quarterly common dividend of $0.63 per share, payable May 15, 2026, to shareholders of record at the close of business April 15, 2026.
This is the 409th consecutive quarterly dividend since 1924 and continues Abbott's streak of increasing dividends for 54 consecutive years; Abbott remains in the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE: ABT) reported late-breaking clinical results (Feb 6, 2026) showing strong safety and efficacy for two AFib ablation devices: the Volt™ Pulsed Field Ablation (PFA) System and the TactiFlex™ Duo Ablation Catheter, Sensor Enabled.
Key highlights: Volt showed 84.2% freedom from rhythm recurrence in PAF and ~68% in persistent AF at 12 months, 6% repeat ablation rate, and marked AFEQT QoL improvements. TactiFlex Duo showed 81% freedom from recurrence in PAF at six months and supported CE Mark approval.
Abbott (NYSE: ABT) reported fourth-quarter 2025 and full-year results and issued 2026 guidance. 4Q25 GAAP diluted EPS $1.01; adjusted diluted EPS $1.50 (+12%). Full-year 2025 GAAP diluted EPS $3.72; adjusted diluted EPS $5.15 (+10%). Full-year 2025 sales were $44.3 billion (+5.7% reported; +5.5% organic). Abbott projects 2026 organic sales +6.5% to +7.5% and adjusted diluted EPS $5.55–$5.80 (midpoint ≈ +10%). Company expects Exact Sciences acquisition to close in Q2 2026 and noted FDA approval for the Volt PFA System and CE Mark for TactiFlex Duo.
Abbott (NYSE: ABT) received CE Mark on Jan 20, 2026 for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled, enabling commercial use in the European Union for treating atrial fibrillation (AFib).
TactiFlex Duo delivers dual-energy therapy (radiofrequency and pulsed field ablation) and completed its first commercial EU cases this week. CE Mark was supported by the FOCALFLEX CE Mark study showing clinically meaningful safety and effectiveness. The catheter integrates with Abbott's EnSite™ X mapping system. Abbott previously secured Volt PFA System approvals in 2025 and obtained FDA Breakthrough Device designation for VT in Oct 2025.
Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, 2026, before the market opens.
The results will be followed by a live webcast of the earnings conference call at 8:00 a.m. Central / 9:00 a.m. Eastern, accessible via Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later the same day.